{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:38:48Z","timestamp":1790303928861,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,10]]},"DOI":"10.7759\/cureus.96514","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T01:16:29Z","timestamp":1762823789000},"source":"Crossref","is-referenced-by-count":2,"title":["Triple M Syndrome After Immune Checkpoint Inhibition: A Rare and Life-Threatening Triad of Myocarditis, Myositis, and Myasthenia Gravis"],"prefix":"10.7759","author":[{"given":"Eman","family":"Albastaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishu","family":"Rishu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yati","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alend","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakya","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi L","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al.. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018, 378:2078-92. 10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx008","article-title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","volume":"28","author":"Hui R","year":"2017","unstructured":"Hui R, Garon EB, Goldman JW, et al.. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017, 28:874-81. 10.1093\/annonc\/mdx008","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa M","year":"2025","unstructured":"Furlepa M, Watts I, Carr AS. Management of triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis. Cancers (Basel). 2025, 17:2063. 10.3390\/cancers17132063","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004729","article-title":"Durvalumab-induced triple-M syndrome","volume":"11","author":"Adeoye FW","year":"2024","unstructured":"Adeoye FW, Jaffar N, Surandran S, Begum G, Islam MR. Durvalumab-induced triple-M syndrome. Eur J Case Rep Intern Med. 2024, 11:004729. 10.12890\/2024_004729","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18999\/nagjms.87.1.156","article-title":"A case of severe immune-related adverse events, myocarditis with myositis, and myasthenia gravis overlap syndrome following adjuvant nivolumab administration for muscle-invasive bladder cancer","volume":"87","author":"Kamikawa H","year":"2025","unstructured":"Kamikawa H, Matsukawa Y, Nishii H, et al.. A case of severe immune-related adverse events, myocarditis with myositis, and myasthenia gravis overlap syndrome following adjuvant nivolumab administration for muscle-invasive bladder cancer. Nagoya J Med Sci. 2025, 87:156-62. 10.18999\/nagjms.87.1.156","journal-title":"Nagoya J Med Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-023-02257-z","article-title":"Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature","volume":"23","author":"Cuenca JA","year":"2023","unstructured":"Cuenca JA, Hanmandlu A, Wegner R, et al.. Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature. BMC Anesthesiol. 2023, 23:310. 10.1186\/s12871-023-02257-z","journal-title":"BMC Anesthesiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/5399073","article-title":"Immunotherapy-induced overlap syndrome: myositis, myasthenia gravis, and myocarditis-a case series","volume":"2024","author":"Aggarwal N","year":"2024","unstructured":"Aggarwal N, Bianchini D, Parkar R, Turner J. Immunotherapy-induced overlap syndrome: myositis, myasthenia gravis, and myocarditis-a case series. Case Rep Med. 2024, 2024:5399073. 10.1155\/2024\/5399073","journal-title":"Case Rep Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000204031","article-title":"Triple M syndrome with triple seronegative myasthenia gravis presenting as a non-ST elevation myocardial infarction","volume":"100","author":"Carranza-Renteria O","year":"2023","unstructured":"Carranza-Renteria O, Mattner O, Sial N, Babici D, Dragomir R, Rodriguez-Hernandez A, Hammond T. Triple M syndrome with triple seronegative myasthenia gravis presenting as a non-ST elevation myocardial infarction. Neurology. 2023, 100:P1-8.002. 10.1212\/WNL.0000000000204031","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2024-260349","article-title":"Triple M overlap syndrome following pembrolizumab treatment: importance of multidisciplinary approach","volume":"18","author":"G\u00f3mez L","year":"2025","unstructured":"G\u00f3mez L, Lozano T, Jovani V, Mart\u00ednez-Banaclocha N. Triple M overlap syndrome following pembrolizumab treatment: importance of multidisciplinary approach. BMJ Case Rep. 2025, 18:e260349. 10.1136\/bcr-2024-260349","journal-title":"BMJ Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2024.12.017","article-title":"Characterization of cardiovascular events and prognosis in immune checkpoint inhibitor-related myocarditis","author":"Pereyra Pietri M","year":"2025","unstructured":"Pereyra Pietri M, Farina JM, Scalia IG, et al.. Characterization of cardiovascular events and prognosis in immune checkpoint inhibitor-related myocarditis. Mayo Clin Proc. 2025, 10.1016\/j.mayocp.2024.12.017","journal-title":"Mayo Clin Proc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak R","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021, 26:1052-61. 10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7530","article-title":"A rare presentation of triple M syndrome from pembrolizumab","volume":"211","author":"Sahota R","year":"2025","unstructured":"Sahota R. A rare presentation of triple M syndrome from pembrolizumab. Am J Respir Crit Care Med. 2025, 211:A7530. 10.1164\/ajrccm.2025.211.Abstracts.A7530","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.47795\/NOJK8575","article-title":"Triple M (myocarditis-myositis-myasthenia gravis) syndrome: a severe immune-mediated toxicity in cancer immunotherapy, a diagnostic challenge","author":"Varghese V","year":"2025","unstructured":"Varghese V, Anpalakhan S, Osman C. Triple M (myocarditis-myositis-myasthenia gravis) syndrome: a severe immune-mediated toxicity in cancer immunotherapy, a diagnostic challenge. Adv Clin Neurosci Rehabil. 2025, 10.47795\/NOJK8575","journal-title":"Adv Clin Neurosci Rehabil"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76834","article-title":"Triple M overlap syndrome: myocarditis, myositis and myasthenia gravis after a single administration of pembrolizumab","volume":"17","author":"Baptista C","year":"2025","unstructured":"Baptista C, Margarido I, Bizarro R, Branco FP, Faria A. Triple M overlap syndrome: myocarditis, myositis and myasthenia gravis after a single administration of pembrolizumab. Cureus. 2025, 17:e76834. 10.7759\/cureus.76834","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427727-triple-m-syndrome-after-immune-checkpoint-inhibition-a-rare-and-life-threatening-triad-of-myocarditis-myositis-and-myasthenia-gravis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T01:16:30Z","timestamp":1762823790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427727-triple-m-syndrome-after-immune-checkpoint-inhibition-a-rare-and-life-threatening-triad-of-myocarditis-myositis-and-myasthenia-gravis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.96514","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}